European Patent Office grants new CRISPR/Cas9 patent (EP 4 289 948) to CVC, with broad claims covering guide RNAs and their combination with Cas9. Patent strengthens CVC’s leading position in European CRISPR IP landscape, providing security to over 150 ERS Genomics licensees.   DUBLIN, IRELAND and CHESHIRE, UK – ERS Genomics (‘ERS’), which was established to provide broad access to the foundational CRISPR/Cas9 intellectual property developed by Prof. Emmanuelle Charpentier announced today that the European Patent Office (‘EPO’) has published its decision to grant patent number EP 4 289 948. The divisional patent includes broad independent claims covering single guide